ClinicalTrials.gg
Active, not recruitingNCT06215118Updated Sep 15, 2026

A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)

A Phase 1 interventional study of Elranatamab and Iberdomide in Multiple Myeloma, sponsored by Pfizer. Active, not recruiting at 43 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing elranatamab in Multiple Myeloma — 21 open to participants now, 25 under way, 5 of them phase 3. elranatamab · Multiple Myeloma.

Enrollment
12th of 31
100 · median 75
Started
2024
with 4 others
Phase 1
5 of 31
2 open now
Primary completion
2027-11
later than 9 of 24 live
Registered
17th of 31
by date
Lead sponsor
13 of 31
Pfizer

Among the 31 studies testing elranatamab in Multiple Myeloma, this one is the 12th largest by enrollment, is one of 5 that started in 2024, is one of 5 in phase 1, reaches primary completion later than 9 of the 24 other live ones, and was the 17th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

21 of the 31 studies testing elranatamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About elranatamab

elranatamab: first FDA approval 2023 (ELREXFIO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing elranatamab in Multiple Myeloma, or all of them as a file.
02

Study summary

The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide.

There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma.

Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disease or condition that does not respond to treatment. Relapsed means the return of a disease after a period of improvement.

All study medicines are given in cycles that last 28 days. Everyone taking part in this study will receive elranatamab as a shot under the skin. Iberdomide will be taken by mouth once a day for 21 days over a 28-day cycle.

Participants will receive study medicine until:

  • their disease progresses or,
  • they experience unacceptable side effects or,
  • they choose to no longer take part in the study.

The study will look at the experiences of people receiving the study medicines. This will help see if the study medicines are safe and can be used for multiple myeloma treatment.

03

Conditions studied

  • Multiple Myeloma

Keywords

  • elranatamab
  • PF-06863135
  • iberdomide
  • relapsed
  • refractory
  • RRMM
  • BCMA
  • MagnetisMM
  • Bispecific antibody
  • CC-220
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prior diagnosis of multiple myeloma as defined by IMWG criteria
  • based on IMWG criteria as defined by at least 1 of the following:
  • Serum M-protein ≥0.5 g/dL by SPEP
  • Urinary M-protein excretion ≥200 mg/24 hour by UPEP
  • Serum immunoglobulin FLC ≥10 mg/dL (≥100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FL ratio (\<0.26 or >1.65)
  • Part 1: Received 2-4 for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.
  • Part 2: Received 1-3 prior lines of therapy for multiple myeloma, consisting of at least 1 immunomodulatory drug and 1 proteasome inhibitor.
  • performance status 0-1
  • Resolved acute effects of any prior therapy to baseline severity or Grade ≤1

Exclusion criteria

Exclusion Criteria:

  • Plasma cell leukemia, Smoldering multiple myeloma, Waldenström's macroglobulinemia, Amyloidosis, POEMS Syndrome
  • Impaired cardiovascular function or cardiovascular diseases
  • Stem cell transplant within 12 weeks prior to enrollment or active graft vs host disease
  • Participants with any active, uncontrolled bacterial, fungal, or viral infection
  • Any other active within 3 years prior to enrollment, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
  • Previous treatment with:
  • BCMA-directed or CD3 redirecting therapy
  • Iberdomide (CC-220) or Mezigdomide
  • Administration of strong inhibitor or inducer of /5 within 2 weeks prior to dosing and during the study
  • Administration with an product within 30 days preceding the first dose of study intervention
  • Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Part 1 Dose Escalation

    Non-randomized elranatamab plus iberdomide

    Drug: Elranatamab · Drug: Iberdomide

  • Experimental
    Part 2 Dose Randomization

    Randomized elranatamab plus iberdomide

    Drug: Elranatamab · Drug: Iberdomide

Interventions

  • BCMA-CD3 bispecific antibody

    Also known as: PF-06863135

  • cereblon-modulating agent

    Also known as: CC-220, BMS-986382

06

What researchers measure

Primary outcomes

  1. Part 1: Number of participants with dose limiting toxicity (DLT)

    Dose limiting toxicity rate based on dose limiting toxicity evaluable participants

    Time frame: Cycle 1, about 28 days

  2. Part 2: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment

    Number of participants with AE among participants who take at least 1 dose of study intervention. AEs are categorized by seriousness and relationship to treatment. Relatedness to study drug is assessed by investigator.

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment

Secondary outcomes

  1. Part 1: Number of participants with Adverse Events (AE) by Seriousness and Relationship to Treatment

    Number of participants with AE among participants who take at least 1 dose of study intervention. AEs are categorized by seriousness and relationship to treatment. Relatedness to study drug is assessed by investigator.

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment

  2. Part 1 and Part 2: Number of Participants with Adverse Events (AE) characterized by type, frequency, severity

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibly of causal relationship

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment

  3. Part 1 and Part 2: Number of Participants with Clinically Significant Change from Baseline in Laboratory Abnormalities

    Laboratory abnormalities as characterized by type, frequency, severity

    Time frame: Assessed from baseline up to 90 days after last dose of study treatment

  4. Part 1 and Part 2: Percentage of Participants with Objective Response Rate (ORR)

    Percent of participants having confirmed Stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), or Partial Response (PR) per IMWG criteria as determined by investigator

    Time frame: Assessed for approximately 2 years

  5. Part 1 and Part 2: Percentage of Participants with Complete Response Rate (CRR)

    Percent of participants having Complete Response/ Stringent Complete Response (CR+sCR) per IMWG criteria as determined by investigator

    Time frame: Assessed for approximately 2 years

  6. Part 1 and Part 2: Time to Response (TTR)

    For participants with an objective response per IMWG criteria, TTR is the time from first dose to the first documentation of objective response that is subsequently confirmed

    Time frame: Assessed for approximately 2 years

  7. Part 1 and Part 2: Duration of Response (DOR)

    For participants with an objective response per IMWG criteria, DOR is the time from first documentation of objective response that is subsequently confirmed until the first documentation of confirmed progressive disease (PD) per IMWG criteria

    Time frame: Assessed for approximately 2 years

  8. Part 1 and Part 2: Duration of Complete Response (DOCR)

    For participants with a Complete Response/ Stringent Complete Response (CR+sCR) per IMWG criteria, DOCR is the time from the first documentation of CR/sCR that is subsequently confirmed until the first documentation of confirmed progressive disease (PD) per IMWG criteria

    Time frame: Assessed for approximately 2 years

  9. Part 1 and Part 2: Time of Progression Free Survival (PFS)

    Progression free survival (IMWG criteria)

    Time frame: Assessed for approximately 2 years

  10. Part 1 and Part 2: Time of Overall Survival (OS)

    The duration of time from first dose of study treatment to death

    Time frame: Assessed for approximately 2 years

  11. Part 1 and Part 2: Minimal Residual Disease (MRD) Negativity Rate

    The proportion of participants achieving CR+sCR with negative MRD per IMWG sequencing criteria, from the date of first dose until the first documentation of confirmed progressive disease (PD), death, or start of new anticancer therapy.

    Time frame: Assessed for approximately 2 years

  12. Part 1 and Part 2: Concentrations of elranatamab

    Pre-dose and post-dose concentrations of elranatamab

    Time frame: Assessed for approximately 2 years

  13. Part 1 and Part 2: Concentrations of iberdomide

    Pre-dose concentrations of iberdomide

    Time frame: Assessed for approximately 4 months

  14. Part 1 and Part 2: Percentage of participants with positive anti-drug antibodies (ADA) against elranatamab

    Percent of participants with positive ADA to elranatamab when given in combination with iberdomide

    Time frame: Assessed for approximately 2 years

07

Study locations

43 sites
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Nov 2027, 44 months after the start.

Of 212 industry-sponsored phase 1 interventional studies under Multiple Myeloma, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 71. This study's planned 44 months is close to that.

Counting every sponsor, half of 413 studies reached it within 50 months; a quarter within 33 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2024
First posted
Jan 22, 2024
StartActual
Feb 20, 2024
Primary completionEst.
Nov 16, 2027
CompletionEst.
Oct 15, 2028
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06215118
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Jan 22, 2024
Start date
Feb 20, 2024
Primary completion
Nov 16, 2027 (estimated)
Completion
Oct 15, 2028 (estimated)
Last update
Sep 15, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Elranatamab · Iberdomide

Start the discussion